Sartorius Acquires Umetrics for $72.5 Million
Sartorius acquired the Swedish company that specializes in data analytics software for biopharmaceutical development and manufacturing.
On April 3, 2017 Sartorius Stedim Biotech (SSB) announced that it has acquired Umetrics, a specialized provider of data analytics software for development and manufacturing processes. SSB has been a cooperation partner of Umetrics since the end of 2012, distributing and co-marketing their software to players in the biopharmaceutical industry. Umetrics is headquartered in Malmö, Sweden and employs approximately 50 people. Sartorius purchased the company for $72.5 million.
Umetrics software has applications in critical process steps of biopharmaceutical manufacture and development. These steps include cell culture processes and specific purification steps. Applying multivariate data analysis on parameters, such as glucose and lactate, allows process variations and their causes can be displayed in real time. Additionally, design of experiment software permits critical process parameters to be identified and quantified as well as development cycles to be considerably shortened.
Source: Sartorius Stedim Biotech
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
